Cite
992. Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI)
MLA
Jose A Vazquez, et al. “992. Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-Label Study (FURI).” Open Forum Infectious Diseases, vol. 8, Nov. 2021, pp. S586–87. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........bcd53821bc9c90cd5d5a015001230747&authtype=sso&custid=ns315887.
APA
Jose A Vazquez, Oliver Cornely, Philipp Koehler, Riina Rautemaa-Richardson, Rohit Bazaz, G Marshall Lyon, Francisco M Marty, Isabel H Gonzalez-Bocco, Rachel Miller, Thomas J Walsh, Peter Pappas, Todd P McCarty, John W Sanders, Caryn Morse, Luis Ostrosky-Zeichner, Robert Krause, Jürgen Prattes, Andrej Spec, David Andes, … David A Angulo. (2021). 992. Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI). Open Forum Infectious Diseases, 8, S586–S587.
Chicago
Jose A Vazquez, Oliver Cornely, Philipp Koehler, Riina Rautemaa-Richardson, Rohit Bazaz, G Marshall Lyon, Francisco M Marty, et al. 2021. “992. Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-Label Study (FURI).” Open Forum Infectious Diseases 8 (November): S586–87. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........bcd53821bc9c90cd5d5a015001230747&authtype=sso&custid=ns315887.